Home › Myasthenia Gravis › California
Pag-aaral pangklinika para sa Myasthenia Gravis sa California
20 pag-aaral para sa Myasthenia Gravis ang naghahanap ng mga kalahok sa mga site sa California.
Mga Lungsod sa California
- Orange6 pag-aaral
- San Francisco6 pag-aaral
- Los Angeles4 pag-aaral
- Mountain View4 pag-aaral
- Carlsbad3 pag-aaral
- Pasadena3 pag-aaral
Opisyal na teksto ng pag-aaral (English)
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
- Neurology Center of North Orange County, Fullerton
- The Neurology Group, Pomona
Nagre-recruitPhase 3
Edad 18 hanggang 74 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07217587A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
- Cinical Study Site, Pasadena
Nagre-recruitPhase 3
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07647510ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- Profound Research LLC - Carlsbad, Carlsbad
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT07294170ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- Profound Research LLC - Carlsbad, Carlsbad
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT07284420A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
- Tri Valley Neurology Medical Associates Inc., Mission Hills
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 11, 2026 · NCT07501702A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- TG Therapeutics Investigational Trial Site, La Jolla
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06680037Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
- University of California Irvine Medical Center, Irvine
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 21, 2026 · NCT06414954A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
- Hoag Memorial Hospital Presbyterian, Newport Beach
- Stanford Neuroscience Health Center, Palo Alto
Nagre-recruitPhase 1
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Ago 14, 2026 · NCT07304154RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- University of California Irvine, Orange
- UC Davis, Department of Neurology, Sacramento
- University of California, San Francisco, San Francisco
Nagre-recruitPhase 1/2
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Ago 13, 2026 · NCT06359041Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)
- University of California-San Francisco, San Francisco
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 64 · Kababaihan · Na-update Ago 11, 2026 · NCT06940323Study of Aritinercept in Patients With Generalized Myasthenia Gravis
- Aurinia Investigational Site, Pasadena
Nagre-recruitPhase 1/2
Edad 18 hanggang 85 · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT07596901A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
- Lucile Packard Children's Hospital Stanford, Palo Alto
- UCSF Benioff Children's Hospital, San Francisco
Nagre-recruitPhase 2/3
Edad 2 hanggang 17 · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT05265273Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1010, Carlsbad
- Site Number - 1028, Irvine
- Site Number - 1023, Los Angeles
- at 2 pa
Nagre-recruitPhase 3
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Hul 30, 2026 · NCT07039916KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
- Ronald Reagan UCLA Medical Center, Los Angeles
- University of California, Irvine, Orange
- Stanford University Medical Center, Palo Alto
Nagre-recruitPhase 2/3
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Hul 29, 2026 · NCT06193889A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Care Access Research, Pasadena
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 27, 2026 · NCT04951622A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
- University of Southern California, Los Angeles
- University of California Irvine, Orange
- University of California San Francisco (UCSF), San Francisco
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 18, 2026 · NCT06456580A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
- UCLA Medical Center, Los Angeles
- University of California, Irvine, Orange
- Stanford Hospital, Palo Alto
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 25, 2026 · NCT06626919Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
- Clinical Trial Site, Fresno
- Clinical Trial Site, Orange
- Clinical Trial Site, Rancho Mirage
- at 1 pa
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 18, 2026 · NCT04202341A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
- UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center - Brain Tumor Center,, San Francisco
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 17, 2026 · NCT06298565Vitaccess Real MG Registry
- UCI Health, Orange
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 29, 2025 · NCT06064461Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.